The company’s Express Screening Antibodies service is designed to address the persistent friction between initial binding data and actual drug development. By digitizing and scaling the early-stage characterization process, the platform allows laboratories to process larger candidate sets and refine their focus toward the most promising molecules.

Chief Executive Officer Emily Leproust noted that the service provides the speed and scalability necessary for researchers to iterate more effectively. By moving from sequence to actionable data in under a week, the firm intends to optimize how development resources are allocated, effectively prioritizing high-potential antibodies early in the research pipeline.